GNH USA

Europe — EMA

Mitoxantrone Accord Healthcare

GNH USA supplies Mitoxantrone Accord Healthcare (Mitoxantrone), an antineoplastic for acute myeloid leukemia and breast cancer. Request a quote for supply.

Mitoxantrone

Request sourcing

1
Pack/s

What is Mitoxantrone?

Mitoxantrone, the active ingredient in Mitoxantrone Accord Healthcare, is a anthracenedione presented as a intravenous solution for intravenous use. It treats acute myeloid leukemia, acute lymphoblastic leukemia, metastatic breast cancer and non‑Hodgkin lymphoma in adult patients.

GNH USA supplies Mitoxantrone Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

What is Mitoxantrone used for?

Mitoxantrone is employed in the treatment of hematologic malignancies and selected solid tumours. - Acute myeloid leukemia: induces remission by disrupting DNA synthesis in leukemic cells. - Acute lymphoblastic leukemia: helps achieve disease control through DNA intercalation. - Metastatic breast cancer: slows tumour progression by inhibiting cell proliferation. - Non‑Hodgkin lymphoma: contributes to tumour regression via topoisomerase II inhibition.

What are the side effects of Mitoxantrone?

Mitoxantrone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting. - Fatigue and weakness. - Alopecia (hair loss). - Myelosuppression leading to anemia, neutropenia or thrombocytopenia. - Mild hepatic enzyme elevation. - Injection site irritation.

Serious or Rare Side Effects: - Cardiotoxicity, including reduced left ventricular ejection fraction. - Secondary acute myeloid leukemia or myelodysplastic syndrome. - Severe infections due to profound neutropenia. - Hepatic failure or severe transaminase elevation. - Acute renal insufficiency. - Severe hypersensitivity reactions.

What precautions apply to Mitoxantrone?

Mitoxantrone requires careful monitoring and specific safety measures before and during therapy. - Monitor blood counts: perform regular CBC to detect myelosuppression. - Assess cardiac function: baseline and periodic echocardiograms are recommended. - Evaluate liver enzymes: monitor hepatic function before each cycle. - Avoid use in patients with known hypersensitivity to anthracenediones. - Use caution in patients with renal impairment: adjust dosing as advised. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Mitoxantrone interact with?

Mitoxantrone can interact with other drugs, altering efficacy or toxicity.

Major Interactions (Avoid): - Concurrent DNA‑intercalating agents: additive cytotoxicity. - Combination with anthracyclines: heightened risk of cardiotoxicity. - Co‑administration with other myelosuppressive chemotherapy: severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Use with radiotherapy: increased tissue damage. - Concomitant nephrotoxic drugs: monitor renal function closely. - Drugs that prolong QT interval: observe cardiac rhythm.

Frequently asked questions

What conditions is Mitoxantrone Accord Healthcare used to treat?+
Mitoxantrone Accord Healthcare is indicated for the treatment of acute myeloid leukemia, acute lymphoblastic leukemia, metastatic breast cancer, and non‑Hodgkin lymphoma. It is administered by a qualified healthcare professional as part of a chemotherapy regimen for these malignancies.
How does Mitoxantrone work at the cellular level?+
Mitoxantrone intercalates into DNA and stabilises the DNA‑topoisomerase II complex, preventing the re‑ligation of DNA strands during replication. This creates double‑strand breaks, halts DNA synthesis, and triggers apoptosis in rapidly dividing cancer cells.
What is the typical dosing schedule for Mitoxantrone?+
The dosing schedule for Mitoxantrone is determined by the prescribing oncologist based on the specific cancer type, patient weight, renal and hepatic function, and treatment protocol. Only a qualified healthcare provider can set the appropriate dose and frequency.
Is Mitoxantrone safe to use during pregnancy or breastfeeding?+
The safety of Mitoxantrone in pregnancy and lactation has not been established. It is generally contraindicated in pregnant or nursing women because of potential fetal toxicity and the risk of drug transfer through breast milk. Consultation with a specialist is essential.
How do I order Mitoxantrone Accord Healthcare from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.
How does Mitoxantrone compare with other anthracenediones or chemotherapy agents?+
Mitoxantrone shares a similar DNA‑intercalating mechanism with other anthracenediones but differs in its pharmacokinetic profile and toxicity spectrum. Compared with agents like doxorubicin, Mitoxantrone may have a lower incidence of acute cardiotoxicity but still requires cardiac monitoring and carries a risk of secondary leukaemia.
What are the recommended storage conditions for Mitoxantrone Accord Healthcare?+
Mitoxantrone Accord Healthcare should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution to maintain stability.
How is Mitoxantrone administered to patients?+
Mitoxantrone is supplied as an intravenous solution and must be administered by a qualified healthcare professional. The infusion is typically given over a prescribed period, often diluted in a compatible IV fluid, and monitored for infusion‑related reactions.
What are the most serious risks associated with Mitoxantrone therapy?+
The most serious risks include cardiotoxicity (reduced heart function), secondary acute myeloid leukaemia or myelodysplastic syndrome, severe myelosuppression leading to infections or bleeding, and hepatic or renal failure. Patients should be closely monitored for these events throughout treatment.
Who should not receive Mitoxantrone treatment?+
Patients with known hypersensitivity to Mitoxantrone or other anthracenediones, those with uncontrolled cardiac disease, severe hepatic or renal impairment, or active uncontrolled infections should generally avoid Mitoxantrone. The prescribing physician will assess suitability on an individual basis.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Mitoxantrone
Route
Intravenous Use
Manufacturer
Accord Healthcare Limited
Origin
EU

Related products

Mitoxan

Mitoxan

Mitoxantrone

Medicamerc S.A
EU
Mitoxantron "ebewe"

Mitoxantron "ebewe"

Mitoxantrone

Ebewe Pharma
EU
Mitoxantron Accord

Mitoxantron Accord

Mitoxantrone

Accord Healthcare B.V.
EU
Mitoxantron Ebewe

Mitoxantron Ebewe

Mitoxantrone

Ebewe Pharma
EU